MAPT and Alzheimer disease: These biomarkers were recently placed into a hypothetic biomarker timeline by Jack and colleagues [23], who proposed that the pathological cascade in AD commences with amyloid and tau pathology, followed by neural injury and dysfunction and finally structural alterations (see Figure 1).